Abstract:Background: In clinical practice, the vast array of potential drug combinations necessitates swift and accurate assessments of pharmacokinetic drug-drug interactions (DDIs), along with recommendations for adjustments. Current methodologies for clinical DDI evaluations primarily rely on basic extrapolations from clinical trial data. However, these methods are limited in accuracy owing to their lack of a comprehensive consideration of various critical factors, including the inhibitory potency, dosage, and type of the inhibitor, as well as the metabolic fraction and intestinal availability of the substrate. Objective: This study aims to propose an efficient and accurate clinical pharmacokinetic-mediated DDI assessment tool, which comprehensively considers the effects of inhibitory potency and dosage of inhibitors, intestinal availability and fraction metabolized of substrates on DDI outcomes. Methods: This study focuses on DDIs caused by cytochrome P450 3A4 enzyme inhibition, utilizing extensive clinical trial data to establish a methodology to calculate the metabolic fraction and intestinal availability for substrates, as well as the concentration and inhibitory potency for inhibitors ( K i or k inact / K I ). These parameters were then used to predict the outcomes of DDIs involving 33 substrates and 20 inhibitors. We also defined the risk index for substrates and the potency index for inhibitors to establish a clinical DDI risk scale. The training set for parameter calculation consisted of 73 clinical trials. The validation set comprised 89 clinical DDI trials involving 53 drugs. which was used to evaluate the reliability of in vivo values of K i and k inact / K I , the accuracy of DDI predictions, and the false-negative rate of risk scale. Results: First, the reliability of the in vivo K i and k inact / K I values calculated in this study was assessed using a basic static model. Compared with values obtained from other methods, this study values showed a lower geometric mean fold error and root mean square error. Additionally, incorporating these values into the physiologically based pharmacokinetic-DDI model facilitated a good fitting of the C-t curves when the substrate's metabolic enzymes are inhibited. Second, area under the curve ratio predictions of studied drugs were within a 1.5 × margin of error in 81% of cases compared with clinical observations in the validation set. Last, the clinical DDI risk scale developed in this study predicted the actual risks in the validation set with only a 5.6% incidence of serious false negatives. Conclusions: This study offers a rapid and accurate approach for assessing the risk of pharmacokinetic-mediated DDIs in clinical practice, providing a foundation for rational combination drug use and dosage adjustments.

Cancer informatics for the clinician: an interaction database for chemotherapy regimens and antiepileptic drugs.

Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression

Dcdb: Drug Combination Database

Real-life drug–drug and herb–drug interactions in outpatients taking oral anticancer drugs: comparison with databases

DDInter: an online drug–drug interaction database towards improving clinical decision-making and patient safety

Abstract 4400: Translational drug interaction database (TDID): A knowledgebase for drug interactions

DDInter 2.0: an enhanced drug interaction resource with expanded data coverage, new interaction types, and improved user interface

A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness

An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations

Assessment of potential drug–drug interactions in hospitalized cancer patients

Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study.

Concordance analysis of two databases to search for potential drug interactions in onco-hematologic patients

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management

Potential drug-drug interactions in outpatient lung cancer patients in a university hospital

Drug-drug interaction software in clinical practice: a systematic review

Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions

Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

DDID: a comprehensive resource for visualization and analysis of diet–drug interactions

DBPOM: a Comprehensive Database of Pharmaco-Omics for Cancer Precision Medicine